Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign a consent form agreeing to take part in the study.
• People who have been confirmed through tissue or cell testing to have a type of prostate cancer called adenocarcinoma.
• People whose prostate cancer has spread and is no longer responding to hormone treatment (castration-resistant), and whose cancer has continued to grow after receiving either a hormone-blocking drug (ARPI) or a chemotherapy drug from the taxane family.
• People who have been formally diagnosed with metastatic castration-resistant prostate cancer (cancer that has spread and is not responding to hormone reduction) with documented signs of disease progression.
• People who have either had surgical removal of the testicles or are receiving ongoing hormone therapy that has reduced testosterone to a very low level (below 50 ng/dL or 1.7 nmol/L).
• People who have one or more tumour spots that show up clearly on a PSMA scan, with uptake levels more than twice as high as the surrounding blood pool.
• People with a general health and activity level rated between 0 and 2 on the ECOG scale, meaning they are fully active to capable of limited self-care (confirm with trial site).
• People whose liver, kidneys, and other organs are functioning at a level considered adequate for the trial.
• People with a partner who could become pregnant must ensure that an acceptable method of barrier contraception is used during the study and for 6 months after the last dose of the trial treatment.

Who may not be able to join:

• People whose prostate cancer involves a mixed cell type, such as neuroendocrine prostate cancer.
• People who have any tumour spots that show up on an FDG scan but do not show up on a PSMA scan.
• People who have received another experimental treatment, chemotherapy, targeted therapy, biological therapy, immunotherapy, or radioligand therapy within 28 days or 5 half-lives before the start of the trial (whichever is the longer period) — hormone-suppressing therapy is excepted.
• People who have had conventional external beam radiation therapy, including radiation covering a large area of the body, within 6 weeks before joining the trial.
• People who have not been on a stable dose of bone-targeted therapy for at least 4 weeks before joining the trial.
• People who have a known allergy or sensitivity to the trial treatment or closely related substances.
• People who received a blood transfusion within 28 days before starting the trial, if the transfusion was given solely to help meet the trial's eligibility requirements.
• People whose bone scan shows a pattern called a "superscan," which can indicate very widespread bone involvement (confirm with trial site).
• People who have other serious medical conditions, as assessed by the trial investigator.
• People who have been diagnosed with another cancer that is expected to affect life expectancy or make it harder to assess the prostate cancer.

Important: Always verify eligibility with the trial site directly before applying.